Chronic Idiopathic Constipation Drugs Market Analysis and Forecast 2022
The latest market report published by Credence Research, Inc. "Global Chronic Idiopathic Constipation (CIC) Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022," the chronic idiopathic constipation drugs market was valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4% from 2016 to 2022.
Browse the full report Chronic Idiopathic Constipation (CIC) Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 20162022 at http://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
Growing awareness and increasing incidence and prevalence of chronic idiopathic constipation CIC are the major factors driving the CIC drugs market worldwide. Growth in demand for CIC drugs in Asia Pacific, coupled with the huge gap of unmet needs in the region is expected to serve as a significant opportunity in the global market during forecast period.
In terms of geographical distribution, North America captures over 40% share of the global market revenue. US is the largest national market for CIC drugs due to greater prevalence of lifestyle respective diseases, higher incidence of constipation, higher healthcare spending and rather greater adoption of pharmaceuticals for treating ailments. As per the National Institutes of Health (NIH) CIC affects approximately 63 Mn individuals in the US. On the other hand, growing awareness in the rapidly developing Asian countries such as China and India will create significant growth opportunities in the Asia Pacific market.
In terms of market segmentation by drug type, Lubiprostone drugs segment currently dominates the market. However, the segment due to its relatively lower efficacy, patent loss and growing competition from Linaclotide will lose its dominance in the upcoming future. The Linaclotide drugs market for CIC treatment is anticipated to grow at a CAGR of 7.7% during 2016 2022.
Analyzing the symptoms, constipation is not considered as a disease but a condition, side effect or syndrome. This factor greatly contributes to the lesser visits from patients to address the issue. Thus over 65% of the CIC drugs market is captured by OTC drugs segment. The OTC market is expected to continue to dominate the market at a CAGR of 6.6% during 2016 2022.
The CIC drugs market is currently open for further research and development and thus introduction of novel pharmaceutical solutions. Actavis, Chugai Pharmaceutical, Ferrin International, Synergy Pharmaceuticals and others are among the top payers active in the global chronic idiopathic constipation drugs market.
Request free sample http://www.credenceresearch.com/sample-request/57738
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, weve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Latest Report - http://www.credenceresearch.com/report/airborne-wind-energy-awe-systems-market
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Name: Chris Smith
Designation: Global Sales Manager
by: Chris Smith